Displaying 13 - 24 of 26
Metabolism, Alcohol & Toxicity
6

Boehringer Ingelheim: MASH in focus: novel insights on diagnosis, management and coordinated patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
6

Boehringer Ingelheim: MASH in focus: novel insights on diagnosis, management and coordinated patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
6

Boehringer Ingelheim: MASH in focus: novel insights on diagnosis, management and coordinated patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
6

Boehringer Ingelheim: MASH in focus: novel insights on diagnosis, management and coordinated patient care - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Displaying 13 - 24 of 26